#5



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

JAVITT, Dr. Daniel C., et al.

Appln. No. 10/059,362 Group Art Unit: Not Yet Assigned

Confirmation No.: 8660 Examiner: Not Yet Assigned

Filed: January 31, 2002

For: GLYCINE SITE FULL AGONIST FOR TREATING A PSYCHOSIS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) (substitute for PTO Form 1449) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.


One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a

request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Louis Gubinsky
Registration No. 24,835

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: May 6, 2002

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

OIPE MAY 0 6 2002 PATENT & TRADEMARK OFFICE

Sheet 1 of 1

Complete if Known	
Application Number	10/059,362
Confirmation Number	8660
Filing Date	January 31, 2002
First Named Inventor	JAVITT, Dr. Daniel C.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	A8301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number	Document Number: Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US 5,837,730		11/17/98	Javitt
		US 5,854,286		12/29/98	Javitt et al.
		US 5,051,448		9/24/91	Stashoua
		US 5,015,740		5/14/91	Kennis
		US 5,468,763		11/21/95	Cordi et al.
		US 6,228,875		5/8/01	Tsai et al
		US 6,162,827		12/19/00	Javitt
		US 6,355,681		3/12/02	Javitt
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Foreign Patent Document: Number[4]	Foreign Patent Document: Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation[6]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation[6]
		D'Souza et al., Glycine Site Agonist of the NMDA Receptor; A Review, CNS Drug Review, Vol. 1, No. 2, pages 227-260 (1996)	
		Rockstroh et al., Effects of the Novel NMDA receptor antagonist SDZ EAA 494 on memory and attention in humans, Psychopharmacology, 124, 3, 261-266, 1994; Malhtra et al., NMDA receptor function and human cognition the effects of ketamine in healthy volunteers, Neuropsychopharmacology, 14, 5, 301-307, 1995.	
		Anil K. Malhotra, MD et al., "NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers", Neuropsychopharmacology 1996, Vol. 14, No. 5	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to indicate here if English language Translation is attached.